



Pfizer Inc. Media Contact  
Media: Steven Danehy  
212-733-1538  
[steven.danehy@pfizer.com](mailto:steven.danehy@pfizer.com)

**Pfizer Expands Support for Patients with Gaucher Disease Through New Agreement for ELELYSO**

- - -

***Deal Reinforces Pfizer Commitment to Rare Disease***

NEW YORK, N.Y., October 13, 2015 - Pfizer Inc. (NYSE:PFE) today announced the completion of an agreement with Protalix in which Pfizer will expand its support of ELELYSO™ (taliglucerase alfa) for the Gaucher community. Through this agreement, Pfizer will expand its commercialization rights to include Israel, while Protalix will retain the commercialization rights in Brazil. ELELYSO is the only enzyme replacement therapy (ERT) made with first-of-its-kind-technology called the ProCellEx®\* expression system, using plant cells from carrots. It is manufactured in Israel and is the first prescription medication to receive kosher certification from the Orthodox Union. ELELYSO is approved for long-term treatment of Type 1 Gaucher disease in adults and children in multiple countries around the world and for Type 1 and Type 3 Gaucher disease in Canada.

"We look forward to expanding the availability of ELELYSO and our successful patient support programs to the Gaucher patient community globally," said Michael Goettler, Global Commercial Officer, Global Innovative Pharma Business, Pfizer Inc. "This new agreement underscores Pfizer's long-standing commitment to serving the needs of patients living with rare diseases."

**About Gaucher Disease**

Gaucher disease is an inherited, rare and serious lysosomal storage disorder in humans that impacts approximately 10,000 patients

worldwide, with a concentration of patients in the United States and Israel. It can cause severe and debilitating symptoms, including: enlargement of the liver and spleen, various forms of bone disease, easy bruising, and anemia (a low number of red blood cells). Gaucher disease consists of varying degrees of severity; it has been subdivided into three subtypes - Types 1, 2, and 3 - according to the presence or absence and timing of neurological involvement. Type 1, the most common, is found at a higher frequency among individuals who are of Ashkenazi Jewish ancestry.

### **About ELELYSO**

ELELYSO® (taliglucerase alfa) is a therapeutic recombinant human glucocerebrosidase (GCD) approved for the treatment of Type 1 Gaucher disease. This innovative enzyme replacement therapy is derived from a proprietary plant-based manufacturing platform using a carrot-cell based expression system.

### **INDICATION**

ELELYSO™ is indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.

### **IMPORTANT SAFETY INFORMATION**

Serious hypersensitivity reactions including anaphylaxis have occurred in some patients treated with ELELYSO (taliglucerase alfa) for injection, for intravenous use. When treated with ELELYSO your doctor should monitor you before and after infusion for reactions.

Medical support should be readily available when ELELYSO is given. Discontinue ELELYSO immediately if you show signs or symptoms of anaphylaxis during infusion and get immediate medical care. Signs and symptoms of anaphylaxis included hives, low blood pressure, flushing, wheezing, chest tightness, nausea, vomiting and dizziness.

Signs and symptoms of hypersensitivity included itching, swelling under the skin, flushing, redness, rash, nausea, vomiting, cough, chest tightness and throat irritation. These reactions occurred up to 3 hours after the start of infusion

Management of hypersensitivity reactions is based on the severity of the reaction. Your doctor may manage the reactions by slowing or temporarily stopping the infusion, and/or treating with medications such as an antihistamine, a fever reducer and/or corticosteroids for mild reactions. Treatment with antihistamines and/or corticosteroids prior to infusion with ELELYSO may prevent these reactions from reoccurring. If severe hypersensitivity reactions occur, immediately stop the infusion of ELELYSO and get immediate medical care.

You should be carefully re-evaluated for treatment with ELELYSO if serious or hypersensitivity reactions including anaphylaxis occur.

The most common adverse reactions for ELELYSO are itching, flushing, headache, joint pain, pain in extremity, abdominal pain, vomiting, fatigue, back pain, dizziness, nausea and rash. Vomiting occurred more often in children than adults.

The recommended dosage of ELELYSO for adults and children who are 4 years of age and older and not taking another ERT is 60 units per kg of body weight given every other week as a 60 to 120 minute intravenous infusion.

As with all therapeutic proteins, including (enzyme replacement therapy) ERTs, there is a possibility of developing antibodies to ELELYSO. The relationship between developing antibodies and hypersensitivity reactions is not clear. Your doctor should monitor you for antibodies to ELELYSO if you have developed antibodies or if you have experienced hypersensitivity reactions to ELELYSO or other ERTs.

If you are pregnant, or plan to become pregnant, you should talk to your doctor about potential benefits and risks.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

For full prescribing information click [here](#).

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient. This product information is intended only for residents of the United States.

#### **Pfizer and Rare Diseases**

Rare diseases are among the most serious of all illnesses and impact millions of patients worldwide, representing an opportunity to apply our knowledge and expertise to help make a significant impact in addressing unmet medical needs. The Pfizer focus on rare diseases builds on more than a decade of experience and a global portfolio of more than 20 medicines approved worldwide that treat rare diseases in the areas of hematology, neuroscience, inherited metabolic disorders, pulmonology, and oncology.

#### **Pfizer Inc.: Working together for a healthier world®**

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility

as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at [www.pfizer.com](http://www.pfizer.com).

*DISCLOSURE NOTICE:*

*The information contained in this statement is as of October 13, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.*

*This release contains forward-looking information about an agreement to expand Pfizer's commercialization rights with respect to ELELYSO<sup>™</sup> (taliglucerase alfa), including its potential benefits thereof, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the ability to realize the anticipated benefits of the agreement; the uncertainties inherent in research and development; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of ELELYSO; and competitive developments.*

*A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at [www.sec.gov](http://www.sec.gov) and [www.pfizer.com](http://www.pfizer.com).*

# # # # #